MedTrace Logo

Varenicline and Bupropion for Smoking Cessation

NCT00935818 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 506

Last updated 2014-05-09

Study results available
· View outcomes & findings →

Summary

This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.

Conditions

  • Smoking

Interventions

DRUG

Varenicline

varenicline - 1 mg bid for 12 weeks

DRUG

placebo

placebo for 12 weeks

DRUG

bupropion SR

bupropion sr - 150 mg bid for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Jon Ebbet, MD · Mayo Clinic

  • Dorothy Hatsukami, PhD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935818 on ClinicalTrials.gov